Annual Meeting, American Society of Hematology

Dozens of presentations advance multiple myeloma research at the 2024 American Society for Hematology (ASH) meeting
Patients with multiple myeloma are living longer, thanks to a host of new immunotherapies and targeted drugs. But there is still no cure for the disease. Physician-scientists at Sylvester Comprehensive Cancer Center,
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces an oral presentation and three poster presentations at the American Society of Hematology (ASH) Annual Meeting,
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel) from global clinical trial
Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting
Positive updates across all programs, including updates from ongoing clinical studies and new translational data in preclinical models supporting use in existing and additional indicationsManagement hosted a conference call during the ASH meeting on Sunday,
Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting
Therapeutically relevant levels of Factor VIII (FVIII) activity sustained in ongoing nonhuman primate (NHP) study through more than sixteen
NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting
(NASDAQ: NEO), a leading oncology testing services company, will share its latest research on hematologic malignancies and the prognostic effects of microenvironment signatures in primary central nervous system (CNS) lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting,
BioPharma Dive1d
ASH24: Leukemia drug sequencing, sickle cell questions and a new kind of CAR-T
Data from Eli Lilly and AstraZeneca could help doctors decide treatment order in chronic lymphocytic leukemia. Elsewhere, ...
ReAlta Presenting New Results in aGVHD at American Society of Hematology 2024
By Karen Roman ReAlta Life Sciences said it is presenting new data at the American Society of Hematology (ASH) Annual Meeting ...
STAT3d
Pfizer’s abrupt withdrawal of sickle cell drug Oxbryta called ‘tone deaf’ at ASH conference
SAN DIEGO — Pfizer’s abrupt withdrawal of its sickle cell drug Oxybryta over safety concerns was called “tone deaf” during a ...
EurekAlert!3d
AML, sickle cell disease research among highlights of UC ASH abstracts
University of Cincinnati Cancer Center experts will present abstracts at the 66th American Society of Hematology (ASH) Annual ...
Fred Hutch6d
Fred Hutch PhD student honored by American Society of Hematology
Rasika Venkataraman, a third-year doctoral student working in the lab of Stanley C. Lee, PhD, at Fred Hutch Cancer Center, ...
Business Wire10d
SonoThera Presents New Data at the American Society of Hematology (ASH) Annual Meeting Demonstrating the Potential of Targeted, Ultrasound-Mediated Gene Delivery to Liver
today announced it will present new data on its novel gene delivery platform and therapeutic programs at the 66 th American Society of Hematology (ASH) Annual Meeting and Exposition, being held ...